T. Rowe Price Investment Management
CRSP icon

T. Rowe Price Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

T. Rowe Price Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112M Sell
2,053,017
-899,578
-30% -$47.4M 0.07% 249
2026
Q1 		$140M Sell
2,952,595
-274,000
-8% -$14.5M 0.1% 207
2025
Q4 		$169M Sell
3,226,595
-55,989
-2% -$3.35M 0.11% 182
2025
Q3 		$213M Sell
3,282,584
-400,442
-11% -$23M 0.13% 168
2025
Q2 		$179M Sell
3,683,026
-115,077
-3% -$4.45M 0.11% 191
2025
Q1 		$129M Sell
3,798,103
-13,605
-0.4% -$577K 0.09% 231
2024
Q4 		$150M Buy
3,811,708
+1,074,238
+39% +$50.7M 0.09% 223
2024
Q3 		$129M Buy
2,737,470
+6,818
+0.2% +$346K 0.08% 248
2024
Q2 		$147M Buy
2,730,652
+26,321
+1% +$1.52M 0.09% 218
2024
Q1 		$184M Sell
2,704,331
-906,855
-25% -$64.9M 0.11% 204
2023
Q4 		$226M Sell
3,611,186
-40,647
-1% -$2.25M 0.15% 164
2023
Q3 		$166M Buy
3,651,833
+5,251
+0.1% +$271K 0.12% 201
2023
Q2 		$205M Sell
3,646,582
-17,789
-0.5% -$1.01M 0.14% 166
2023
Q1 		$166M Buy
3,664,371
+670,794
+22% +$32.6M 0.12% 181
2022
Q4 		$122M Buy
2,993,577
+752,132
+34% +$39.9M 0.09% 221
2022
Q3 		$146M Buy
+2,241,445
New +$162M 0.12% 181

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management's CRSP Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its CRISPR Therapeutics (CRSP) stake by 30% in Q2 2026, selling an estimated $47.4M and leaving 2,053,017 shares worth $112M. The position accounts for 0.07% of the portfolio, ranked #249.

T. Rowe Price Investment Management first reported a position in CRSP in Q3 2022 and has held it in 16 quarters since. The position peaked at $226M in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • T. Rowe Price Investment Management held 2,053,017 shares of CRISPR Therapeutics worth $112M as of Q2 2026.
  • T. Rowe Price Investment Management sold 899,578 CRISPR Therapeutics shares in Q2 2026, an estimated $47.4M.
  • CRISPR Therapeutics made up 0.07% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #249 holding.
  • T. Rowe Price Investment Management first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • T. Rowe Price Investment Management's CRISPR Therapeutics position peaked at $226M in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.